You are here

P&T® Journal contents for March 2010


Industry’s Agenda Is Clear, but Its Future Path Is Not
Pharmacists are divided over provisions in the House and Senate health care reform bills, but most agree on the need to expand medication therapy management services, reduce patient readmissions, and provide access to discounted drugs.
Stephen Barlas
Rituximab prolongs survival in patients with aggressive lymphomas, but more study is needed to clarify its effect on survival of patients with indolent lymphomas.
Efrat Dotan, MD, Charu Aggarwal, MD, MPH, and Mitchell R. Smith, MD, PhD
Meeting Highlights
Representative studies focus on aromatase inhibitors, tamoxifen, and bisphosphonates. Agents for pancreatic, colorectal, and gastric cancers are also reviewed.
Walter Alexander
Topics include agents for multiple sclerosis, rheumatoid arthritis, and hypertension.
Marvin M. Goldenberg, PhD, RPh, MS
Continuing Education Credit
Applying the 2010 Joint Commission Patient Safety Goal Requirements
Ensuring continuity of care for patients needing erythrocyte-stimulating agents helps to prevent hemoglobin fluctuations, avoids duplications, and lowers hospital costs.
Shilpa Amara, PharmD, Indu Lew, PharmD, and Robert T. Adamson, PharmD


David B. Nash, MD, MBA, ­discusses an online application that provides important information linking CME, performance improvement, and maintenance of board certification.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, explains how to prevent the accidental infusion of breast milk in newborns.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses how the FDA’s upcoming guidelines for a Risk Evaluation and Mitigation Strategies program could cost hospitals and their pharmacies significant time and money.
Stephen Barlas
From Afluria to Xiaflex, P&T presents the latest studies and information about FDA approvals, drug indications, product recalls, and industry updates.